Comorbidity in rheumatoid arthritis
- PMID: 27045333
- DOI: 10.4414/smw.2016.14290
Comorbidity in rheumatoid arthritis
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory condition, which is associated with an increased risk of comorbidity from other diseases. RA disease severity is a major predictor of development of cardiovascular disease, serious infections and malignant lymphoma. This reflects the role of chronic inflammation in the underlying pathology. Recent surveys indicate that although clinical outcomes have improved in patients with RA, mainly owing to access to more efficient pharmacotherapy, comorbidity remains a major issue in many patients. Register-based observational studies are useful sources of information on the impact of comorbidity and the efficacy and safety of antirheumatic treatment in patients with coexisting diseases. As a part of strategies to improve further the management of patients with RA, multidisciplinary collaboration for prevention and early detection of comorbidities is of major importance.
Similar articles
-
The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference.Rheumatology (Oxford). 2018 Oct 1;57(57 Suppl 7):vii11-vii22. doi: 10.1093/rheumatology/key209. Rheumatology (Oxford). 2018. PMID: 30289537 Review.
-
One year in review 2018: novelties in the treatment of rheumatoid arthritis.Clin Exp Rheumatol. 2018 May-Jun;36(3):347-361. Epub 2018 May 17. Clin Exp Rheumatol. 2018. PMID: 29798748 Review.
-
Comorbidity in psoriatic arthritis and rheumatoid arthritis.Intern Med J. 2018 Nov;48(11):1360-1368. doi: 10.1111/imj.14046. Intern Med J. 2018. PMID: 30047189
-
Safe use of antirheumatic agents in patients with comorbidities.Rheum Dis Clin North Am. 2012 Nov;38(4):771-93. doi: 10.1016/j.rdc.2012.08.013. Epub 2012 Sep 12. Rheum Dis Clin North Am. 2012. PMID: 23137582 Review.
-
[Therapy of rheumatoid arthritis: what influences the risk of infections and malignant neoplasms?].Dtsch Med Wochenschr. 2014 Feb;139(6):268-71. doi: 10.1055/s-0033-1359998. Epub 2014 Jan 28. Dtsch Med Wochenschr. 2014. PMID: 24473846 German. No abstract available.
Cited by
-
Advanced Echocardiography Techniques: The Future Stethoscope of Systemic Diseases.Curr Probl Cardiol. 2022 Jun;47(6):100847. doi: 10.1016/j.cpcardiol.2021.100847. Epub 2021 Mar 30. Curr Probl Cardiol. 2022. PMID: 33992429 Free PMC article. Review.
-
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience.Rheumatol Int. 2021 May;41(5):903-909. doi: 10.1007/s00296-021-04818-2. Epub 2021 Mar 3. Rheumatol Int. 2021. PMID: 33655421 Free PMC article.
-
Lebanese Hospital-Based Rheumatoid Arthritis Registry: Characteristics of Patients and Comparison with Other Populations.Mediterr J Rheumatol. 2022 Jun 30;33(2):218-223. doi: 10.31138/mjr.33.2.218. eCollection 2022 Jun. Mediterr J Rheumatol. 2022. PMID: 36128213 Free PMC article.
-
COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments.Clin Rheumatol. 2020 Jul;39(7):2069-2075. doi: 10.1007/s10067-020-05189-y. Epub 2020 May 29. Clin Rheumatol. 2020. PMID: 32472461 Free PMC article. Review.
-
One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry.Arthritis Res Ther. 2018 Jan 2;20(1):2. doi: 10.1186/s13075-017-1496-5. Arthritis Res Ther. 2018. PMID: 29329557 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
